Back to Journals » Cancer Management and Research » Volume 12

Review

Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments

       
Total article views   HTML views PDF downloads Totals
9,060 Dovepress* 7,244+ 961 8,205
PubMed Central* 1,816 386 2,202
Totals 9,060 1,347 10,407
*Since 8 December 2020
Total mentioned Facebook Delicious Reddit Twitter Others
22 0 0 0 8 14

View citations on PubMed Central and Google Scholar